Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Echocardiography During Ajmaline Test

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03491475
Recruitment Status : Recruiting
First Posted : April 9, 2018
Last Update Posted : April 9, 2018
Information provided by (Responsible Party):
Esther Scheirlynck, Universitair Ziekenhuis Brussel

Brief Summary:
In this study the investigators analyse echocardiographic images before and during Ajmaline test. The purpose is to know if any echocardiographic modifications are present during either negative or positive Ajmaline testing.

Condition or disease Intervention/treatment
Brugada Syndrome Drug: Ajmaline test

Detailed Description:
The diagnosis of Brugada Syndrome is made when a type 1 pattern is present on the electrocardiogram (ECG), either spontaneously or after administration of a sodium channel blocker. For pathofysiological understanding, the investigators will analyse echocardiography images before and during the administration of Ajmaline. Comparing echocardiographies before and during negative Ajmaline test, will allow the investigators to indentify the effect of Ajmaline administration on cardiac function. The comparison between images of negative and positive Ajmaline tests will expose differences related to the occurence of a type 1 ECG.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Dynamicity of Echocardiography During Ajmaline Test
Actual Study Start Date : March 26, 2018
Estimated Primary Completion Date : March 31, 2019
Estimated Study Completion Date : May 31, 2019

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Negative Ajmaline test
No appearance of a type 1 ECG during Ajmaline test
Drug: Ajmaline test
Administration of Ajmaline
Other Name: Echocardiography

Positive Ajmaline test
Appearance of a type 1 ECG during Ajmaline test
Drug: Ajmaline test
Administration of Ajmaline
Other Name: Echocardiography

Primary Outcome Measures :
  1. Speckle tracking strain measurement [ Time Frame: 1 day at the time of enrollment ]
    Cardiac function assessed by speckle tracking peak strain and peak strain dispersion

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients referred for Ajmaline test, either because of symptoms or in the context of familial screening.

Inclusion Criteria:

  • >17 years old
  • clinical indication for Ajmaline test

Exclusion Criteria:

  • History of right ventricular outflow tract ablation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03491475

Layout table for location contacts
Contact: Esther Scheirlynck, MD +3228012461
Contact: Ingrid Lemoine

Layout table for location information
UZ Brussel Recruiting
Jette, Brussels, Belgium, 1090
Contact: Catherine De Greef   
Sponsors and Collaborators
Universitair Ziekenhuis Brussel
Layout table for investigator information
Principal Investigator: Esther Scheirlynck, MD Universitair Ziekenhuis Brussel

Layout table for additonal information
Responsible Party: Esther Scheirlynck, Principal Investigator, Universitair Ziekenhuis Brussel Identifier: NCT03491475    
Other Study ID Numbers: UniverstairZB
First Posted: April 9, 2018    Key Record Dates
Last Update Posted: April 9, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Esther Scheirlynck, Universitair Ziekenhuis Brussel:
Ajmaline test
Additional relevant MeSH terms:
Layout table for MeSH terms
Brugada Syndrome
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Genetic Diseases, Inborn
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action